Results 71 to 80 of about 20,522 (204)

Atherosclerosis: From Pathogenesis to Therapeutic Interventions

open access: yesMedComm, Volume 7, Issue 11, November 2026.
The diagram outlines the core mechanisms driving atherosclerosis, including endothelial dysfunction, inflammatory responses, phenotypic switching of smooth muscle cells, and the gut–vascular axis. It also presents the corresponding therapeutic approaches now under development, such as gene therapies, immunotherapies, and nanotechnology platforms ...
Enge Zhou   +9 more
wiley   +1 more source

The effects of ezetimibe on omega-3 fatty acid absorption in the prevention of cardiovascular disease [PDF]

open access: yes, 2012
Omega-3 polyunsaturated fatty acids like alpha-linolenic acid (ALA) may be beneficial for cardiovascular health. A cholesterol supplemented diet will increase ALA bioavailability. Conversely, drugs which inhibit intestinal cholesterol metabolism may also
Blackwood, David Palmer
core  

Simultaneous Spectrophotometric Determination of Valsartan and Ezetimibe in Pharmaceuticals [PDF]

open access: yes, 2011
Purpose: To develop a direct, simple and extraction-free spectrophotometric method for the simultaneous estimation of valsartan and ezetimibe in pharmaceuticals.Methods: A spectrophotometric method for the determination of valsartan and ezetimibe was ...
Mandal, BK   +2 more
core   +1 more source

STUDYING MOLECULAR MODELLING OF THE CHOLESTEROL ABSORPTION INHIBITOR EZETIMIBE AND EVALUATION OF ITS ANTIBACTERIAL ACTIVITY [PDF]

open access: yesBulletin of Pharmaceutical Sciences. Assiut University
As is known, ezetimibe is the only drug classified as a cholesterol absorption inhibitor, working by preventing the cholesterol transporter protein Niemann-Pick C1-Like 1 (NPC1L1) from functioning.
Manila Mohammed   +4 more
doaj   +1 more source

Vitamin D: Physiology, Pharmacology and Clinical Evidence for Supplementation—A Narrative Review

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 139, Issue 5, November 2026.
ABSTRACT Vitamin D is a nutrient and prohormone obtained from diet and supplements and synthesized in the skin. It is essential for calcium and phosphate homeostasis and skeletal health and influences multiple extra‐skeletal processes, yet deficiency remains common worldwide.
Jyrki K. Virtanen
wiley   +1 more source

Ezetimibe and simvastatin for the prevention of cardiovascular events in predialysis chronic kidney disease patients: a review

open access: yes, 2012
Sahar Naderi,1 JoAnne M Foody21Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, OH, USA; 2Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USAAbstract: The majority of chronic kidney disease ...
Foody JM, Naderi S
core  

Effect of ezetimibe on cholesterol transit in mice.

open access: yes, 2016
A, An illustrated protocol for the 3H-cholesterol distribution assay. B, Upper; 3H-decay per minute (DPM) count distribution 3 h after 3H-cholesterol was given orally to C57BL/6J mice.
Hiraku Ono (3214602)   +6 more
core   +1 more source

Pharmacokinetic non-interaction analysis in a fixed-dose formulation in combination of atorvastatin and ezetimibe

open access: yesFrontiers in Pharmacology, 2014
Recent clinical research has shown that atorvastatin in combination with cholesterol absorption inhibitor ezetimibe significantly reduces LDL-C level in patients with hypercholesterolemia, showing a superior lipid-lowering efficacy compared to statin ...
Omar ePatiño-Rodríguez   +4 more
doaj   +1 more source

Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real‐Life Experience From a National Reference Network

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10318-10329, November 2026.
ABSTRACT Aim Lipodystrophy syndromes are rare diseases with metabolic and cardiovascular consequences. This study explores the metabolic and renal effects of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with genetic lipodystrophy. Patients and Methods Patients with familial partial lipodystrophy (n = 57) or congenital generalised ...
Léna Robert   +12 more
wiley   +1 more source

Bowel Obstruction/Ileus Associated With the Use of Glucagon‐Like Peptide‐1 Receptor Agonists: A Nationwide Database Study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 9941-9954, November 2026.
ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy